发明名称 |
MetAP-2 inhibitor polymersomes for therapeutic administration |
摘要 |
Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. |
申请公布号 |
US9272050(B2) |
申请公布日期 |
2016.03.01 |
申请号 |
US201414495725 |
申请日期 |
2014.09.24 |
申请人 |
CHILDREN'S MEDICAL CENTER CORPORATION |
发明人 |
Benny-Ratsaby Ofra;D'Amato Robert;Folkman Judah |
分类号 |
A61K31/77;A61K47/48;A61K31/336 |
主分类号 |
A61K31/77 |
代理机构 |
Nixon Peabody LLP |
代理人 |
Nixon Peabody LLP ;Resnick David S.;FitzGerald Mark J. |
主权项 |
1. A composition formulated for oral administration comprising a fumagillol derivative having anti-proliferative activity, wherein said fumagillol derivative is covalently linked to a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety, wherein said block copolymer is a diblock copolymer comprising a PEG-PLA diblock copolymer having hydrophilic PEG and hydrophobic PLA moieties, and wherein said fumagillol derivative is covalently linked with the hydrophobic moiety of said block copolymer. |
地址 |
Boston MA US |